Results 81 to 90 of about 21,604,258 (289)
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy ...
Elaine Tan Su Yin +2 more
doaj +1 more source
FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu +14 more
wiley +1 more source
Barriers to Chimeric Antigen Receptor T-Cell Therapy
This cohort study examines barriers to access of CAR T-cell therapy among patients with hematologic cancer referred for this treatment.
Valtis, Yannis K. +26 more
openaire +3 more sources
Cytokine signaling in chimeric antigen receptor T-cell therapy
Abstract Adoptive immunotherapy using chimeric antigen-receptor (CAR)-engineered T cells can induce robust antitumor responses against hematologic malignancies. However, its efficacy is not durable in the majority of the patients, warranting further improvement of T-cell functions.
openaire +2 more sources
Mechanisms of failure of chimeric antigen receptor T-cell therapy [PDF]
Purpose of review Although chimeric antigen receptor T (CART)-cell therapy is best recognized for its antitumor effect in relapsed/refractory B-cell hematological cancers, it is still associated with a high relapse rate. Recent findings We firstly analyzed internal immunological and
Li, Xiaoqing, Chen, Weihong
openaire +2 more sources
Multifunctional oral delivery system—L. reuteri@ZGM—act as both a carrier and therapeutic adjuvant, providing ROS scavenging, and mucin‐interactive properties tailored to the IBD microenvironment. This bioactive gel safeguards L. reuteri from gastric degradation, enhances mucosal adhesion, and promotes long‐term retention at inflamed sites, thereby ...
Mengyun Peng +8 more
wiley +1 more source
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi +7 more
doaj +1 more source
Repurposing the dense tumor stroma from a physical barrier into an anchoring scaffold, an engineered oncolytic adenovirus encoding IL15C‐CBD overcomes the immunosuppressive microenvironment in triple‐negative breast cancer. Intratumoral viral replication secretes this collagen‐anchored immunocytokine, forming a localized cytokine depot.
Yaqi Yang +14 more
wiley +1 more source
Lactate‐driven endometrial cancer relapse is mediated by enzymatic protein modification. Elevated lactate levels activate AARS1, which catalyzes K280 lactylation of IGF2BP3, therefore stabilizing HMGA2 mRNA and promoting tumor stemness and recurrence.
Peng Jiang +11 more
wiley +1 more source
Magnetically guided macrophage immunobots integrate active tumor targeting with immunometabolic therapy. After systemic administration, magnetic actuation enhances immunobot retention and tumor penetration, while LPS‐functionalized FePt microrollers sustain M1‐like polarization through inflammatory and iron‐amplified oxidative signaling and trigger ...
Xirui Zeng +7 more
wiley +1 more source

